Champions Oncology to Announce Fourth Quarter and Year-End Financial Results on Wednesday, July 23, 2025
Champions Oncology (CSBR), a global preclinical and clinical research services provider specializing in oncology solutions, has scheduled its fourth quarter and year-end financial results announcement for Wednesday, July 23, 2025, after market close.
The company will host a conference call at 4:30 P.M. EDT to discuss the results. Investors can join via phone using access code 792442 or listen to the replay within 72 hours through the company's website or by dialing with passcode 52754.
Champions Oncology (CSBR), fornitore globale di servizi di ricerca preclinica e clinica specializzato in soluzioni oncologiche, ha programmato l'annuncio dei risultati finanziari del quarto trimestre e dell'intero anno per mercoled矛 23 luglio 2025, dopo la chiusura del mercato.
L'azienda terr脿 una conference call alle 16:30 EDT per discutere i risultati. Gli investitori potranno partecipare telefonicamente utilizzando il codice di accesso 792442 o ascoltare la registrazione entro 72 ore tramite il sito web della societ脿 o componendo il numero con il codice 52754.
Champions Oncology (CSBR), proveedor global de servicios de investigaci贸n precl铆nica y cl铆nica especializado en soluciones oncol贸gicas, ha programado el anuncio de sus resultados financieros del cuarto trimestre y del a帽o completo para el mi茅rcoles 23 de julio de 2025, despu茅s del cierre del mercado.
La compa帽铆a realizar谩 una llamada conferencia a las 4:30 P.M. EDT para discutir los resultados. Los inversionistas pueden unirse por tel茅fono usando el c贸digo de acceso 792442 o escuchar la repetici贸n dentro de las 72 horas a trav茅s del sitio web de la empresa o marcando con el c贸digo 52754.
Champions Oncology (CSBR)電� 膦呾枒頃� 靻旊（靺橃潉 鞝勲鞙茧 頃橂姅 旮�搿滊矊 鞝勳瀯靸� 氚� 鞛勳儊 鞐瓣惮 靹滊箘鞀� 鞝滉车鞐呾泊搿�, 2025雲� 7鞗� 23鞚� 靾橃殧鞚� 鞛� 毵堦皭 頉� 4攵勱赴 氚� 鞐半 鞛 鞁れ爜 氚滍憸毳� 鞓堨爼頃橁碃 鞛堨姷雼堧嫟.
須岇偓電� 瓴瓣臣毳� 雲检潣頃橁赴 鞙勴暣 霃欕秬 響滌鞁� 旮办 鞓ろ泟 4鞁� 30攵�鞐� 旎嵓霟办姢 旖滌潉 臧滌禍頃� 鞓堨爼鞛呺媹雼�. 韴瀽鞛愲摛鞚� 鞝戩啀 旖旊摐 792442毳� 靷毄頃橃棳 鞝勴檾搿� 彀胳棳頃橁卑雮� 須岇偓 鞗轨偓鞚错姼鞐愳劀 72鞁滉皠 鞚措偞鞐� 鞛癌靻§潉 霌ｊ卑雮� 牍勲皜氩堩樃 52754搿� 鞝勴檾頃橃棳 觳法頃� 靾� 鞛堨姷雼堧嫟.
Champions Oncology (CSBR), fournisseur mondial de services de recherche pr茅clinique et clinique sp茅cialis茅 dans les solutions en oncologie, a pr茅vu d鈥檃nnoncer ses r茅sultats financiers du quatri猫me trimestre et de l鈥檃nn茅e compl猫te le mercredi 23 juillet 2025, apr猫s la cl么ture du march茅.
L鈥檈ntreprise tiendra une conf茅rence t茅l茅phonique 脿 16h30 EDT pour discuter des r茅sultats. Les investisseurs peuvent participer par t茅l茅phone en utilisant le code d鈥檃cc猫s 792442 ou 茅couter la rediffusion dans les 72 heures via le site web de la soci茅t茅 ou en composant le code secret 52754.
Champions Oncology (CSBR), ein globaler Anbieter von pr盲klinischen und klinischen Forschungsdienstleistungen mit Schwerpunkt auf Onkologiel枚sungen, hat die Bekanntgabe der Finanzergebnisse f眉r das vierte Quartal und das Gesamtjahr f眉r Mittwoch, den 23. Juli 2025, nach B枚rsenschluss geplant.
Das Unternehmen wird um 16:30 Uhr EDT eine Telefonkonferenz abhalten, um die Ergebnisse zu besprechen. Investoren k枚nnen sich telefonisch mit dem Zugangscode 792442 einw盲hlen oder die Aufzeichnung innerhalb von 72 Stunden 眉ber die Website des Unternehmens oder mit dem Passwort 52754 anh枚ren.
- None.
- None.
HACKENSACK, NJ / / July 21, 2025 / Champions Oncology, Inc. (CSBR), a global preclinical and clinical research services provider that offers end-to-end oncology solutions, will report its financial and operational results for the quarter and year ended April 30, 2025, on Wednesday, July 23, 2025, after market close. The company will host a conference call to discuss the results that day at 4:30 P.M. EDT (1:30 P.M. PDT). To join the call dial 888-506-0062 (Domestic) or 973-528-0011 (International) and enter the access code 792442. A replay of the call will be available by dialing 877-481-4010 (Domestic) or 919-882-2331 (International) and entering passcode: 52754, or by accessing the investors section of the company's website within 72 hours.
About Champions Oncology, Inc.
Champions Oncology is a global preclinical and clinical research services provider that offers end-to-end oncology R&D solutions to biopharma organizations. With the largest and most annotated bank of clinically relevant patient-derived xenograft (PDX) and primary hematological malignancy models, Champions delivers innovative highest-quality data through proprietary in vivo and ex vivo platforms. Through its large portfolio of cutting-edge bioanalytical platforms, groundbreaking data platform and analytics, and scientific excellence, Champions enables the advancement of preclinical and clinical oncology drug discovery and development programs worldwide. For more information, please visit .
Media Inquiries:
Gavin Cooper
Vice President, Global Marketing
[email protected]
Website:
Facebook:
LinkedIn:
Twitter:
Instagram:
SOURCE: Champions Oncology, Inc.
View the original on ACCESS Newswire
FAQ
When will Champions Oncology (CSBR) release Q4 and year-end 2025 earnings?
How can investors join Champions Oncology's Q4 2025 earnings call?
Where can I find the replay of Champions Oncology's Q4 2025 earnings call?
What period will Champions Oncology's earnings report cover?
